Maimon Research LLC is a long established boutique consulting company specializing in health technology assessment, together with advising and implementing market access strategies to support pharmaceutical products and devices over their life cycle.

The focus of Maimon Research is on developing claims for pharmaceutical products and devices that are credible, evaluable and replicable.

This sets Maimon Research apart from other health technology assessment consultants. Unlike competitors, Maimon Research offers a unique and methodologically acceptable approach to the validation and replication of health technology claims.

This approach puts to one side the modeling of non-testable claims which, unfortunately, have come to dominate the pharmacoeconomics literature and the content of global value dossiers, in favor of credible claims which meet the standards of normal science.

Although supported by groups such as the Academy of Managed Care Pharmacy (AMCP) in their Format for Formulary Submissions and the Institute for Clinical and Economic Review (ICER), modeled claims which fail to generate testable predictions have no place in health technology assessment. Such claims are typically ignored by PBMs and formulary comittees as irrelevant to decision making.

They are best seen as thought experiments (or imaginary worlds or speculative fiction). Why?  Because we have no idea as to whether the modeled claim is right, or even whether it is wrong! Such claims, even if justified by the realism of the model generating such claims, have the potential to mislead formulary committees. Unfortunately, we have no idea as to how misleading the claims are, in particular those for comparative product effectiveness, actually – which leads, obviously, to the likelihood that, on such a weak (or absent) evidence base formulary decisions to be challenged.

The focus of developing value claims for product impacts that are testable is entirely consistent with the standards of normal science and not intelligent design. Such an approach provides clients with a firm evidence base to support pricing decisions, formulary placement and support for products over their life cycle

Maimon Research recognizes that in the focus of models that generate testable claims much of what we have been taught under the rubric of ‘health technology assessment’ or ‘pharmacoeconomics’ over the past 20-25 years has to be put to one side; a prospect that may face significant opposition. This is a challenge that has to be met; we have to abandon thought experiments in favor of techniques for product impact that are testable and which meet the same evidentiary standards that underpin randomized clinical trials.    

In providing clients with the tools, including the drafting of validation protocols to support comparative product claims, Maimon Research can provide a range of other services to support market access and a favorable formulary position,. As detailed in this website, these include critical assessments of global value dossiers, global electronic databases and, econometric modeling for burden of illness and retrospective evaluations of product impact.